The healthcare company's corporate venturing unit is among the investors in Assembly's first major funding round.
Johnson & Johnson Development Corporation, the venture capital subsidiary of healthcare company Johnson & Johnson, has participated in a financing round for Assembly Pharmaceuticals, a US-based virology-focused biopharmaceutical company.
The exact investment sum wasn’t disclosed, but the round, Assembly’s first, was also supported by venture capital firm BioCrossroads, Twilight Venture Partners, Luson Bioventures and a handful of private individuals.
Assembly will use the investment to advance its research into a cure for hepatitis B, which affects 350 million people worldwide.…
